President Trump intends to nominate Heidi Overton, a deputy director on the White House Domestic Policy Council, to be FDA commissioner after months of leadership turnover. Overton’s visible role in an executive order to reduce the recommended childhood vaccine schedule and split the MMR shot has sparked debate and drawn criticism. Analysts and some senators warn the confirmation could be contentious, while supporters praise her character; the White House says additional FDA appointments are forthcoming.
Trump Nominates Heidi Overton to Lead FDA Amid Vaccine Controversy and Leadership Turmoil
Photo by Jim WATSON / AFP via Getty Images
President Donald Trump plans to nominate Heidi Overton, a deputy director on the White House Domestic Policy Council, to serve as commissioner of the U.S. Food and Drug Administration (FDA). The selection, reported by Axios, comes after months of turnover at the agency and has already generated both criticism and support.
Background
Marty Makary resigned as FDA commissioner earlier this year, leaving several senior posts unfilled. Kyle Diamantas is serving as acting commissioner and has worked to repair the agency’s relationship with the pharmaceutical sector. Overton’s nomination is intended to bring a permanent leader to the troubled agency.
Controversy Over Vaccines
Overton played a visible role at the signing of a recent executive order that would reshape the federally recommended childhood vaccine schedule. The directive proposes reducing the total number of recommended childhood vaccinations and separating the combined measles-mumps-rubella (MMR) shot into three individual inoculations, a proposal that has sparked debate among public health experts and lawmakers.
"We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out," Overton said at the signing ceremony.
Reactions and Confirmation Outlook
The nomination has drawn immediate criticism from some quarters. Chris Meekins, a Raymond James analyst and former Trump health official, told Axios that Overton "has degrees but seemingly no real experience running anything," and warned the pharmaceutical industry may view the pick with concern. Supporters, including Brian Blase of the Paragon Health Institute, have publicly endorsed her character and commitment to improving patient care.
Senate confirmation could be contentious. Outgoing Senate Health Committee Chair Bill Cassidy called last week’s vaccine executive order "wrong," and Overton’s prominent role in that event may intensify opposition during confirmation hearings. A senior administration official indicated that the White House expects to nominate additional leaders for other vacant FDA roles as it seeks to stabilize the agency.
As the nomination advances, lawmakers, industry groups, and public health experts will likely scrutinize Overton’s policy positions and management experience. The choice highlights broader questions about the FDA’s future direction and its relationship with the pharmaceutical industry.
Help us improve.
